CS
VIVO

Candriam SCA’s Meridian Bioscience Inc VIVO Stock Holding History

Candriam SCA’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-46,000
Closed -$787K – 639
2015
Q3 		$787K Hold
46,000
– – 0.02% 468
2015
Q2 		$857K Buy
+46,000
New +$853K 0.02% 470

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Candriam SCA's VIVO Position: Q4 2015 in Review

Candriam SCA sold out of Meridian Bioscience Inc (VIVO) in Q4 2015, closing a stake of 46,000 shares — an estimated $787K sold.

Candriam SCA first reported a position in VIVO in Q2 2015 and held it in 2 quarters. The position peaked at $857K in Q2 2015. 176 funds tracked by Wall St. Rank hold VIVO as of Q4 2015.

  • Candriam SCA reported no remaining Meridian Bioscience Inc position as of Q4 2015 after selling out during the quarter.
  • Candriam SCA sold 46,000 Meridian Bioscience Inc shares in Q4 2015, an estimated $787K.
  • Candriam SCA first reported a position in Meridian Bioscience Inc in Q2 2015 and held it in 2 quarters.
  • Candriam SCA's Meridian Bioscience Inc position peaked at $857K in Q2 2015.
  • 176 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2015.

Based on Candriam SCA's 13F filing for Q4 2015, filed 25 Jan 2016.